• Blog
  • Cancer Immunotherapy Market Forecast | 2023-28

    Cancer Immunotherapy Market Forecast | 2023-28

    Cancer Immunotherapy Market Forecast | 2023-28
    Report code - SR1999 Delivery - 2 Weeks
    Cancer Immunotherapy Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth See more...

    Market Insights

    The cancer immunotherapy market is estimated to grow from USD 134.95 billion in 2022 to USD 273.32 billion by 2028 at a CAGR of 12.33% during the forecast period.

    Wish to get a free sample? Register here. 

    What is cancer immunotherapy?

    Cancer immunotherapy, also known as immuno-oncology, is a cancer treatment that uses a person’s immune system to prevent, control, and fight cancer. Cancer immunotherapy is a type of biological therapy, that uses substances made from living organisms to boost the immune system in order to eradicate cancer.

    Cancer Immunotherapy Market Report Overview

    Market Size in 2028

    USD 273.32 billion

    Market Size in 2022

    USD 134.95 billion

    Market Growth (2023-2028)

    CAGR 12.33%

    Base Year of Study

    2022

    Trend Period

    2017-2021

    Forecast Period

    2023-2028

    Key Players

    The following are some of the key players in the market:

    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Co.
    • ELI Lilly and Company
    • F Hoffman-La Roche Ltd.
    • Janssen Global Services, LLC (Johnson and Johnson)
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc

    Market Dynamics

    The cancer immunotherapy market is driven by tremendous growth and development by several factors. The major drivers of the cancer immunotherapy market are:

    • A significant market driver for immunotherapy is the global increase in cancer incidence.
    • Significant developments in the field of cancer immunotherapy research have resulted in the development of innovative and modern therapies.
    • The development and acceptance of immunotherapies have received support from regulatory agencies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
    • With the increasing adoption of combination therapies, clinical trials have shown positive outcomes when immunotherapy is combined with other treatments such as chemotherapy or radiation therapy or with numerous immunotherapeutic drugs.

     

    To learn more about this report, request a free sample here.

    Compared to immunotherapies, cancer treatment alternatives including chemotherapy and radiation therapy are more frequently employed despite having higher negative effects. The former is based on the elimination of cancer cells through surgery, chemotherapy, or radiation. These treatments can efficiently kill or eliminate cancer cells, but their use is frequently limited since they also frequently kill significant numbers of healthy cells. Immunotherapies are preferred above other treatment alternatives because they work by boosting the body's natural defenses with the help of synthetic proteins like monoclonal antibodies.

    In summary, the cancer immunotherapy market is being pushed by a combination of several scientific discoveries, rising demand for effective cancer therapies, regulatory backing, and expenditures in research & development. These elements together contributed to the market's growth and expansion.

    What Stimulates the Growing Demand for Cancer Immunotherapy in Hospitals?

    Hospitals are still the most preferred medical setting since these facilities have the most cutting-edge technology for accurate diagnosis and treatment. The high adoption of cutting-edge treatments, diagnostics, and medical technology, supported by public and private funding, raises the standard of healthcare provided by hospitals.

    By 2031, hospitals are anticipated to account for about 61% of the market for cancer immunotherapy as a result of a combination of these variables. It is anticipated that a larger patient base will choose clinic-based healthcare due to the relatively short wait times and convenience of scheduling appointments. Clinicians are focusing on providing cancer immunotherapy to patients due to the steadily increasing demand for high-quality cancer therapies, which is fueling the exponential adoption of these treatments.

    Segment Analysis

    Want to know the most attractive market segments? Register here.

    By Drug Type

    The market is bifurcated into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, cell therapies, immunomodulators, and interferons alpha.

    Monoclonal antibodies held the major share of the market in 2022, and are expected to remain the biggest demand generator for the cancer immunotherapy market in the foreseen future. Key factors such as cost-effectiveness and increasing investments in the R&D of monoclonal antibodies are expected to drive market growth in the coming years.

    By Diagnosis Type

    The market is segmented as lung cancer, breast cancer, multiple myeloma, colorectal cancer, head & neck cancer, prostate cancer, melanoma, and other cancer types.

    Lung cancer captured the largest share of the cancer immunotherapy market in 2022, due to factors such as the increasing number of patients suffering from lung diseases. The segment is likely to remain dominant during the forecast period, owing to the growing awareness of the early therapeutics of lung cancer.

    By End-User Type

    The market is segmented into hospitals, clinics, and others. Among these end-user types, hospital dominates the market and is expected to grow with the highest CAGR during the forecast period. Hospitals are highly preferred for cancer immunotherapy, and the rising demand for cancer immunotherapy in hospitals is expected to drive market growth over the forecast period.

    Regional Analysis

    North America is expected to remain the largest market for cancer immunotherapy over the forecast period. Major factors such as the rising incidence of cancer, increasing demand for modern cancer therapeutics, and growing geriatric population are fuelling the growth of the regional cancer immunotherapy market. 


    Know which region offers the best growth opportunities. Register here.

    Segmentation

    The market is segmented into the following categories:

    By Drugs Class Type

    • Monoclonal Antibodies 
    • Cancer Vaccines 
    • Checkpoint Inhibitors 
    • Cell Therapies 
    • Immunomodulators 
    • Interferons Alpha 

    By Diagnosis Type

    • Lung Cancer 
    • Breast Cancer 
    • Multiple Myeloma 
    • Colorectal Cancer 
    • Head & Neck Cancer 
    • Prostate Cancer 
    • Melanoma 
    • Other Cancer Types 

    By End-User Type

    • Hospitals 
    • Clinics 
    • Others 

    By Region

    • North America (Country Analysis: The USA, Canada, and Mexico)
    • Europe (Country Analysis: Germany, France, The UK, Russia, Italy, and the Rest of Europe)
    • Asia-Pacific (Country Analysis: China, Japan, India, South Korea, and the Rest of Asia-Pacific)
    • Rest of the World (Country Analysis: Brazil, Argentina, and Others)

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

    We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

    Report Features

    This report provides intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the dynamics and will enable strategic decision-making for the existing players and those willing to enter the market.

    What Deliverables will you get in this report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth Analysis of the Cancer Immunotherapy Market 

    How lucrative is the future?

    The market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional, and country-level historical data and forecasts

    Which are the most attractive market segments?

    Market segment analysis and Forecast

    Which are the top players and what is their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirement?

    10% free customization

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

    Custom Research: Stratview research offers custom research services across the sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@Stratviewresearch.com

    Frequently Asked Questions (FAQs)

    Cancer immunotherapy, also known as immuno-oncology, is a cancer treatment that uses a persons immune system to prevent, control, and fight cancer. Cancer immunotherapy is a type of biological therapy, that uses substances made from living organisms to boost the immune system in order to eradicate cancer.

    Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co., ELI Lilly and Company, F Hoffman-La Roche Ltd., Janssen Global Services, LLC (Johnson and Johnson), Merck & Co., Inc., Novartis AG, and Pfizer Inc. are some of the key players in the market.

    North America is estimated to be the dominant market in the coming years.

    A significant market driver for immunotherapy is the global increase in cancer incidence. Significant developments in the field of cancer immunotherapy research have resulted in the development of innovative and modern therapies. The development and acceptance of immunotherapies have received support from regulatory agencies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). With the increasing adoption of combination therapies, clinical trials have shown positive outcomes when immunotherapy is combined with other treatments such as chemotherapy or radiation therapy or with numerous immunotherapeutic drugs.

    Cancer immunotherapy market was estimated to grow at a CAGR of 12.33% from 2023-2028.

    The study period of this market report is 2017-28.

    Hospital is likely to maintain its dominance in the market in the next five years.

    The cancer immunotherapy market is estimated to grow from USD 134.95 billion in 2022 to USD 273.32 billion by 2028